In a filing, Tscan Therapeutics Inc revealed its 10% Owner Lynx1 Capital Management LP acquired Company’s shares for reported $0.29 million on Dec 13 ’24. In the deal valued at $2.90 per share,100,000 shares were bought. As a result of this transaction, Lynx1 Capital Management LP now holds 5,357,347 shares worth roughly $12.86 million.
Then, Lynx1 Capital Management LP bought 31,800 shares, generating $95,629 in total proceeds. Upon buying the shares at $3.01, the 10% Owner now owns 5,257,347 shares.
Before that, Lynx1 Capital Management LP bought 947 shares. Tscan Therapeutics Inc shares valued at $4,114 were divested by the 10% Owner at a price of $4.34 per share. As a result of the transaction, Lynx1 Capital Management LP now holds 5,225,547 shares, worth roughly $12.54 million.
BTIG Research initiated its Tscan Therapeutics Inc [TCRX] rating to a Buy in a research note published on May 16, 2024; the price target was $12. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid May with a ‘”a Buy”‘ rating. Wedbush began covering TCRX with “an Outperform” recommendation on June 22, 2023.
Price Performance Review of TCRX
On Friday, Tscan Therapeutics Inc [NASDAQ:TCRX] saw its stock fall -2.44% to $2.40. Over the last five days, the stock has lost -13.36%. Tscan Therapeutics Inc shares have fallen nearly -21.05% since the year began. Nevertheless, the stocks have fallen -58.76% over the past one year. While a 52-week high of $9.69 was reached on 01/03/25, a 52-week low of $2.43 was recorded on 01/17/25. SMA at 50 days reached $3.81, while 200 days put it at $5.94.
Levels Of Support And Resistance For TCRX Stock
The 24-hour chart illustrates a support level at 2.35, which if violated will result in even more drops to 2.31. On the upside, there is a resistance level at 2.47. A further resistance level may holdings at 2.55. The Relative Strength Index (RSI) on the 14-day chart is 25.28, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.33, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.59%. Stochastics %K at 3.65% indicates the stock is a buying.
How much short interest is there in Tscan Therapeutics Inc?
A steep rise in short interest was recorded in Tscan Therapeutics Inc stocks on 2024-12-31, growing by 0.2 million shares to a total of 2.52 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-29 was 2.32 million shares. There was a rise of 8.0%, which implies that there is a positive sentiment for the stock.
